NCT03768531View on ClinicalTrials.gov

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 14, 2019

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Resectable Biliary Tract Cancer
Interventions
DRUG

Nivolumab

Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).

DRUG

Cabrilizumab

Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03768531 - Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | Biotech Hunter | Biotech Hunter